- Home
- FVRR vs PHAR Comparison
FVRR vs PHAR Comparison
Compare FVRR & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FVRR
- PHAR
- Stock Information
- Founded
- FVRR 2010
- PHAR 1988
- Country
- FVRR Israel
- PHAR Netherlands
- Employees
- FVRR N/A
- PHAR N/A
- Industry
- FVRR Business Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- FVRR Consumer Discretionary
- PHAR Health Care
- Exchange
- FVRR Nasdaq
- PHAR Nasdaq
- Market Cap
- FVRR 933.7M
- PHAR 951.7M
- IPO Year
- FVRR 2019
- PHAR N/A
- Fundamental
- Price
- FVRR $22.69
- PHAR $13.41
- Analyst Decision
- FVRR Buy
- PHAR Strong Buy
- Analyst Count
- FVRR 11
- PHAR 3
- Target Price
- FVRR $32.91
- PHAR $30.00
- AVG Volume (30 Days)
- FVRR 558.6K
- PHAR 12.4K
- Earning Date
- FVRR 11-05-2025
- PHAR 11-06-2025
- Dividend Yield
- FVRR N/A
- PHAR N/A
- EPS Growth
- FVRR 70.84
- PHAR N/A
- EPS
- FVRR 0.50
- PHAR N/A
- Revenue
- FVRR $419,126,000.00
- PHAR $339,836,000.00
- Revenue This Year
- FVRR $12.80
- PHAR $17.70
- Revenue Next Year
- FVRR $6.58
- PHAR $12.25
- P/E Ratio
- FVRR $46.63
- PHAR N/A
- Revenue Growth
- FVRR 12.60
- PHAR 22.44
- 52 Week Low
- FVRR $20.83
- PHAR $7.31
- 52 Week High
- FVRR $36.11
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- FVRR 44.49
- PHAR 42.50
- Support Level
- FVRR $21.70
- PHAR $13.96
- Resistance Level
- FVRR $23.26
- PHAR $14.70
- Average True Range (ATR)
- FVRR 0.73
- PHAR 0.51
- MACD
- FVRR -0.07
- PHAR -0.20
- Stochastic Oscillator
- FVRR 36.64
- PHAR 10.28
About FVRR Fiverr International Ltd. no par value
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Wiring and Translation, and Video and Animation among others.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.